Effect of aspirin on renal function and the prostaglandin-kallikrein systems early after myocardial infarction.
Using a double-blind procedure, 29 patients with a recent myocardial infarction were randomly allocated to a placebo group (n = 14) and to a group receiving aspirin, 300 mg three times a day (n = 15) over 7 days. No change in renal function was observed in either treatment group. Compared with the placebo group, the 24-h urinary excretion of prostaglandin E2 (PGE2) was significantly suppressed in the aspirin group, but the urinary kallikrein activity was unchanged. These results contrast with our previous study of similar patients, in which sulfinpyrazone decreased renal function, as well as the urinary PGE2 and kallikrein excretions. These divergent effects of aspirin and sulfinpyrazone on urinary kallikrein activity could explain the different trends in renal function observed early after myocardial infarction.
D000368:Aged; D001241:Aspirin / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015232:Dinoprostone; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007610:Kallikreins / Q000652:urine*; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy / Q000503:physiopathology / Q000652:urine*; D011458:Prostaglandins E / Q000652:urine*; D011897:Random Allocation; D013997:Time Factors
D011458:Prostaglandins E; D007610:Kallikreins; D015232:Dinoprostone; D001241:Aspirin